Buyers’ Clubs and Intermediaries: Why the Structure Changes the Analysis

This page is a warning about buyers’ clubs, pooled purchasing, intermediaries, and redistribution arrangements involving prescription drugs entering the United States. FDA enforcement-discretion policies discussed in connection with individual personal-use shipments should not be treated as permission, authorization, a safe harbor, or a legal pathway. Once a third party, club, pooled order, donation network, prescriber-supply arrangement, or redistribution structure is involved, the legal and regulatory risks materially increase.

What “personal” means in personal importation

FDA guidance discusses limited circumstances in which the agency may consider enforcement discretion for a shipment intended solely for an individual’s own personal use — not for further sale, transfer, or distribution into U.S. commerce.[2] The FDA’s published criteria also require no known commercialization or promotion of the product to U.S. residents.[2] These criteria do not create a legal right to import prescription drugs. They also do not protect arrangements involving a middle party who collects orders, pools funds, receives bulk shipments, coordinates fulfillment, or redistributes medication to others. Admission remains subject to federal enforcement decisions.

Arrangements that fall outside the framework

Several common structures create legal and regulatory risk because each introduces transfer, coordination, or distribution beyond a single individual’s own use. These are structural risk categories based on the FDA’s personal-use and no-commercialization criteria, not a separate FDA-published safe-harbor list:

• Pooled purchasing. Several people combining funds to place a single larger order introduces collective purchasing, coordination, and potential redistribution.
• Charity or donation distribution. Acquiring medication to give, transfer, or supply to others is distribution, even when the motive is charitable.
• Buyers’ clubs. An organized arrangement that obtains, coordinates, supplies, or redistributes medication to members is, by structure, a distribution arrangement.
• Family member importing for another person. Bringing in medication for another person’s use may be treated as third-party transfer or distribution and should not be assumed to fit within FDA personal-use guidance.
• A prescriber importing for patients. Obtaining foreign-sourced medication to supply to patients raises distribution, licensing, prescribing, dispensing, and professional-practice concerns.

In each category, the risk arises from the same structural feature: medication is being coordinated, transferred, supplied, or moved to someone other than a single individual acting only for that individual’s own use. The patient’s medical need, the drug’s identity, the foreign supplier’s status, or the affordability concern does not create a federal safe harbor.

The enforcement mechanism: Import Alert 66-57

The FDA’s principal border tool here is Import Alert 66-57, which directs that divisions may detain without physical examination all dosage forms and shipments — commercial and personal — of foreign-manufactured unapproved prescription drugs from distributors, including online pharmacies, identified on the alert’s Red List.[1] The alert directs personnel to follow the personal-importation guidance in the Regulatory Procedures Manual for personal shipments, while stating that commercial or promotional shipments and products subject to detention without physical examination are generally not amenable to enforcement discretion.[1] A companion alert, Import Alert 66-41, covers unapproved new drugs promoted in the U.S. more broadly.[3]

The alert is directed at distributors and online pharmacies on its Red List, but patients should not read that structure as protection for themselves. The FDA states the alert represents current guidance to field personnel and does not create or confer any rights on any person, nor bind the FDA or the public.[1] It is an enforcement instrument, not a grant of permission. Participation in an intermediary, pooled-purchase, club, or redistribution arrangement does not convert the transaction into protected personal importation and does not insulate the shipment from refusal, detention, destruction, seizure, or other enforcement consequences where applicable.

The AIDS-era buyers’ clubs are not a current model

Buyers’ clubs are associated historically with the AIDS crisis, when patients organized to obtain treatments that were unavailable in the United States. That history should not be treated as a current legal model. Historical references to AIDS-era buyers’ clubs should not be interpreted as evidence that similar arrangements are lawful, authorized, protected, or tolerated under current federal enforcement practices. FDA personal-importation policy has been discussed in connection with situations where effective treatment is not available domestically, which concerns clinical availability rather than affordability.[4] The fact that some historical clubs operated openly is not a basis for treating present-day buyers’ clubs, pooled orders, or cost-driven importation networks as lawful, authorized, protected, or tolerated today. Primary federal documentation of that era is limited, and this page does not make specific claims about historical prosecution or non-action patterns.

This page provides general legal and regulatory risk information drawn from primary federal sources. It is not legal advice or medical advice. It does not authorize, encourage, or instruct any person to import, obtain, possess, transfer, or distribute prescription drugs. Consult a U.S.-licensed attorney for legal questions and a licensed healthcare professional for medical decisions.